Medications

US regulators to decide on new weight loss drug

US regulators were expected to decide Tuesday whether to approve the second new anti-obesity drug in 13 years, Qnexa, which studies have shown may help some people lose up to 10 percent of their body weight.

Medications

Bristol-Myers, Pfizer's Eliquis approved in Japan

Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Medications

FDA backs Vytorin for kidney disease patients

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

Medications

Fearing abuse, US blocks generic OxyContin (Update)

U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.

Medications

FDA approves first generic versions of Cymbalta

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

Medications

US group seeks to block Gilead drug patent in India

A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

Medications

Mining data for the history of pharmaceutical development

(Medical Xpress)—Yale's Michael Kinch spent his spare time in the last year creating a massive database that encompasses the entire history of drug development in the United States. In a series of 20 articles scheduled ...

page 2 from 4